Repligen Extends Long Term Supply Agreement with Purolite for Protein A Ligands
November 07 2017 - 7:30AM
Repligen Corporation (NASDAQ:RGEN) today announced that is has
extended a long-term supply agreement with Purolite Life Sciences
for the manufacture of Protein A ligands at Repligen’s facilities
in Waltham, MA and Lund, Sweden. Repligen is the main strategic
supplier of Protein A ligands to Purolite, an emerging player in
the Protein A resin market with its Praesto® line of modern
agarose-based, high-flow chromatography resins. Pursuant to the
agreement, Repligen will supply Protein A ligands to Purolite
through November 2022, with an option for renewal through 2025.
Protein A chromatography remains the gold standard for monoclonal
antibody purification, consistently providing outstanding
results.
Steve Tingley, VP of Sales for Repligen said, “We are delighted
that Purolite has made the decision to extend our current supply
agreement, which ensures the supply of high quality Protein A
ligands to Purolite for the next five to eight years. This
agreement is supported by Repligen’s business continuity plans,
quality systems and research and development expertise. We look
forward to building on our relationship with Purolite, both as
their primary Protein A ligand supplier and through the recently
announced collaboration with Purolite on OPUS® pre-packed
columns.”
Chris Major, VP of Sales for Purolite, said “In 2015, we signed
our first supply agreement with Repligen. They were a natural
choice for us due to their reputation in the industry for quality
and reliability, coupled with the fact they are the largest
producer worldwide of Protein A ligands. Purolite has benefited
from Repligen’s unmatched expertise in ligand development and
manufacturing, and their ability to provide dual site supply for
critical raw materials, scalable manufacturing capacity and
flexibility -- all of which are key considerations as we prepare to
further penetrate the chromatography resin market. Today, our
Praesto® resins continue to gain rapid traction in the industry and
in response to customer requests, this extended agreement enhances
our commitment to the security of supply of our highly competitive
agarose-based Protein A resins.”
About Repligen Corporation
Repligen Corporation (NASDAQ:RGEN) is a global
bioprocessing company that develops and commercializes highly
innovative products that deliver cost and process efficiencies to
biological drug manufacturers worldwide. Our portfolio includes
protein products (Protein A affinity ligands, cell culture growth
factors), chromatography products (OPUS® pre-packed columns,
chromatography resins, ELISA kits) and filtration products (XCell™
ATF systems, TangenX™ Sius™ flat sheet TFF cassettes, and Spectrum
KrosFlo™ hollow fiber TFF cartridges and systems). The Protein A
ligands and growth factor products that we produce are key
components of Protein A affinity resins and cell culture media,
respectively. Protein A affinity resins are the industry standard
for downstream separation and purification of monoclonal
antibody-based therapeutics. Growth factors are used in upstream
processes to accelerate cell growth and productivity. Our
innovative line of OPUS® chromatography columns, used in downstream
processes for bench-scale through clinical-scale purification
needs, are delivered pre-packed to our customers with their choice
of resin and bed height. Our XCell™ ATF Systems, available in
stainless steel and single-use configurations, continuously
eliminate waste from a bioreactor to concentrate cells and
significantly increase productivity in upstream processes.
Single-use Sius™ TFF cassettes and hardware are used for biologic
drug concentration in downstream filtration processes. Spectrum
KrosFlo™ TFF cartridges and systems are used in both upstream and
downstream filtration processes. Repligen’s corporate headquarters
are in Waltham, MA (USA), with additional administrative and
manufacturing operations in Shrewsbury, MA, Rancho Dominguez, CA,
Lund, Sweden and Weingarten, Germany.
This press release may contain forward-looking
statements within the meaning of the federal securities laws.
Investors are cautioned that statements in this press release which
are not strictly historical statements including, without
limitation, express or implied statements regarding future
financial performance and our collaboration with Purolite and
statements identified by words like “believe,” “expect,” “may,”
“will,” “should,” “seek,” or “could” and similar expressions,
constitute forward-looking statements. Such forward-looking
statements are subject to a number of risks and uncertainties that
could cause actual results to differ materially from those
anticipated, including risks discussed in our most recent Annual
Report on Form 10-K on file with the Securities and Exchange
Commission and the other reports that we periodically file with the
Securities and Exchange Commission. We expressly disclaim any
responsibility to update any forward-looking statements, except as
required by law.
Source: Repligen Corporation Sondra Newman Senior Director
Investor Relations(781) 419-1881 snewman@repligen.com
Repligen (NASDAQ:RGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Repligen (NASDAQ:RGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024